If you’ve ever wondered whether your hormones change how a psychedelic feels, you’re asking a good question, and scientists have only recently started asking it too. Here is what the research shows so far, and where it runs out.
The serotonin connection
Psilocybin and mescaline share a main target, the serotonin 2A receptor, also known as 5-HT2A. Researchers believe classic psychedelics, including psilocybin, mescaline, LSD, and others, exert their core effects through 5-HT2A receptor agonism.
That shared target is where the similarity ends, and I’ll get to the differences below. Estrogen and progesterone also interact with the serotonin system, which is why researchers are finally suspecting your cycle may influence your experience.
A recent review in Trends in Pharmacological Sciences put it this way: the serotonin system that psychedelics engage may not be sex-neutral, and it can be shaped by sex and hormonal state depending on brain region, receptor, and context. That review also noted the studies come mostly from animals, with limited human data.
What the mouse studies found
Much of the evidence comes from rodents, which is where the serotonin sensitivity findings you may have heard about originate. A 2026 review of rodent research found that the strongest predictor of whether a sex difference showed up was the phase of the estrous cycle, not sex alone. That included a split between two phases in psilocybin-induced head twitches, a behavior researchers use as a marker of 5-HT2A activation.
The likely explanation is estradiol. The same review explains that estradiol raises 5-HT2A receptor expression and boosts serotonin activity by increasing the enzyme that makes serotonin, inhibiting the serotonin transporter, and suppressing monoamine oxidase A.
Put simply, more estrogen may mean more serotonin available and more receptors for psilocin, the active form of psilocybin, to act on.
There is an important caveat for microdosers. In a study of male and female mice, females showed more head twitches at high doses, but the researchers found no substantial sex differences in potency, and commonly used doses produced comparable effects in both sexes. Whatever differences exist may show up more at larger doses than at the low end.
What we know in humans
Human evidence is thinner and a bit mixed. PET imaging suggests baseline 5-HT2A binding doesn’t differ significantly between men and women, but estradiol levels correlate positively with receptor density.
A 2026 review in Molecular Psychiatry adds that 5-HT2A availability appears higher in low-progesterone states and lower in progesterone-dominant or low-estrogen states.
The cycle itself has barely been studied. One published case series of three women reported a return of periods after amenorrhea, an early period when psychedelics were taken in the luteal phase, and more regular cycles in a woman with PCOS. Three women is an early signal, not a pattern. Trials are underway, including a study tracking symptoms across two menstrual cycles in people who microdose.
Two registered trials are studying microdosing in women with premenstrual symptoms, there is no proven protocol, and the largest placebo-controlled microdosing study found expectation explained much of the benefit.
Despite the lack of research, many women are describing real changes, and those experiences deserve respect, and a place at the table, to help improve continued research studies and trials.
It’s too early to draw definitive conclusions – but ask any of the thousands of women microdosing to support their hormonal health – and you might not even need the research to be convinced.
How mescaline works differently from psilocybin
Psilocybin and mescaline are often grouped together because they share that 5-HT2A target. But, their chemistry and their wider effects are different. Get ready for a chemistry lesson – which admittedly, was my weakest school subject – enjoy!
Think of your brain as running on chemical messengers. Each one fits into its own kind of docking spot, called a receptor, a bit like a key fitting a lock. Serotonin is one messenger. Dopamine and norepinephrine (a close relative of adrenaline) are others.
Psilocybin is shaped a lot like serotonin, so it mostly works through the serotonin locks. Mescaline is shaped more like dopamine and norepinephrine. In lab studies, it does fit the same serotonin locks that psilocybin uses, called 5-HT2A and 5-HT2C. It also fits some of the locks for norepinephrine and adrenaline, called adrenergic receptors.
One early study, a preprint that other scientists haven’t reviewed yet, reported that mescaline fits one type of adrenergic lock, alpha-2, and another spot called TAAR1. TAAR1 sits in the brain’s dopamine pathways and helps manage how dopamine gets used, which is how mescaline may connect to dopamine, though probably indirectly. A separate study of mescaline’s chemical cousins found they also fit two more adrenergic locks, alpha-1A and alpha-2A. That may change how these compounds feel alongside their serotonin effects.
That’s the current best explanation for a dopamine and adrenergic connection. It looks indirect, and most of it comes from lab and animal studies.
Here is what has been measured in humans. In a study of 32 healthy volunteers, mescaline, LSD, and psilocybin at psychoactive-equivalent doses produced comparable subjective effects overall, but they differed in other ways:
- Duration. Mescaline lasted longest, about 11 hours on average, compared with about 8 for LSD and about 5 for psilocybin.
- Potency and onset. Mescaline is roughly 30 times less potent than psilocybin, so it’s used at much higher doses, and it can take longer to kick in.
- Oxytocin. Mescaline and LSD raised circulating oxytocin. Psilocybin did not.
- Body effects. All three moderately raised blood pressure, body temperature, and pupil size. Mescaline caused slightly more mild after-effects over the following 12 to 24 hours, such as nausea and headache.
Because the pharmacology differs, it makes sense to think of these as different tools instead of a ranking or an either-or choice. A more purely serotonergic medicine and one that also touches adrenergic and dopamine-related systems might suit different people, or different moments in a cycle or life stage.
That’s a reasonable hypothesis, and it is still a hypothesis. In that same study, the overall experience was hard to tell apart at matched strength, no one has studied mescaline’s non-serotonin effects across the menstrual cycle, and none of this has been tested at microdose levels.
The adrenergic piece is also a good reason to take cardiovascular health seriously. Classic psychedelics as a group have sympathomimetic effects, meaning they can raise heart rate and blood pressure. If you have a heart condition or high blood pressure, talk with your provider before trying any of them.
If you’re curious about mescaline, one practical note: peyote is a slow-growing cactus under real conservation pressure and is sacred to the Native American Church. Many people choose San Pedro or other sources to honor that lineage – and the non-peyote form of mescaline is the only medicine decriminalized in Colorado for use outside of the Native American Church.
What this means for you
Nothing here says psilocybin or mescaline supports, balances, or fixes hormones. What the research supports is a more modest idea: your hormonal state may shape how your body responds, and different medicines may act differently, so tracking your own patterns is worth it.
- Keep a simple log of cycle day, sleep, mood, and energy alongside anything you take.
- Compare across at least two cycles, ideally three, before drawing conclusions.
- If you try more than one medicine, give each its own tracking period so you can tell them apart.
- If you use hormonal birth control, hormone therapy, or any prescription, talk with your prescriber first. Interactions are poorly studied.
- Start low, change one variable at a time, and give yourself permission to pause.
Some women also build a wider hormonal-health routine that includes sleep, nutrition, and stress support. This becomes part of a holistic microdosing approach to wellness and if you’d like support for building this into your life, 1:1 microdose coaching or the Embodied Microdosing Program may be right for you.
For our favorite microdosing products, visit Golden Rule Mushrooms and get an extra 10% discount off your cart.
Disclosure: I’m an affiliate partner of Golden Rule Mushrooms, and proceeds from this partnership support Colorado Sisters in Psychedelics. This post is educational and not medical advice.
Microdosing for Women series
Part 1: Microdosing and Your Menstrual Cycle
Part 2: Psilocybin, Mescaline, and Women’s Hormones (you are here)
Part 3: Microdosing Through Perimenopause and Menopause
Part 4: A Cycle-Aware Microdosing Journal
Sources
- Sex-dependent effects of psychedelics: rodent review, Frontiers in Psychiatry, 2026: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1824073/full
- Psychedelic-like effects in male and female C57BL/6J mice: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449377/
- Sex-sensitive serotonergic signaling, Trends in Pharmacological Sciences: https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(26)00175-6
- Psychedelics and women’s mental health, Molecular Psychiatry, 2026: https://www.nature.com/articles/s41380-026-03801-2
- Hormonal influences on psilocybin responsivity across the female lifespan, Psychoactives, 2025: https://doi.org/10.3390/psychoactives4040039
- APRA menstrual cycle and microdosing study: https://apra.science/microdosing-and-the-menstrual-cycle/
- Comparative acute effects of mescaline, LSD, and psilocybin, Neuropsychopharmacology, 2023: https://www.nature.com/articles/s41386-023-01607-2
- Receptor interaction profiles of mescaline derivatives, Frontiers in Pharmacology, 2021: https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/
- Behavioral pharmacology of mescaline, bioRxiv preprint (not peer reviewed), 2024: https://www.biorxiv.org/content/10.1101/2024.08.28.610032v1.full
- Safety pharmacology of acute mescaline administration, British Journal of Clinical Pharmacology, 2024: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.16349
- Cardiovascular safety of psychedelic medicine: https://pmc.ncbi.nlm.nih.gov/articles/PMC10661823/
